Evidence map›Paper›PMID 33027039›Full record

ArticleJMIR cancer2020

The Impact of COVID-19 on Cancer Screening: Challenges and Opportunities.

Ramon S Cancino, Zhaohui Su, Ruben Mesa, Gail E Tomlinson, Jing Wang

Registry-linked trialAbstract read
In one paragraph

Article in JMIR cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04683744 (Facilitators and Barriers to Cancer Screening), which is not on this map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04683744 completednot on this mapstarted 2021, after this paper: background citation

Facilitators and Barriers to Cancer Screening: Stakeholder Perspectives on Implementation

TypeobservationalSponsorIndiana UniversityRan2021 to 2023Enrolled82ConditionsColorectal Cancer ScreeningArmsSemi-structured interviews-Patients, Semi-structured interviews-Health system
3 · Its place in the literature

Who cites it

100 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Non-speculum sampling approaches for cervical screening in older women: randomised controlled trial.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ramon S CancinoDepartment of Family & Community Medicine, Joe R & Teresa Lozano Long School of Medicine, UT Health San Antonio, San Antonio, TX, United States.ORCID https://orcid.org/0000-0002-5758-5025
Zhaohui SuCenter on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, TX, United States.ORCID https://orcid.org/0000-0003-2005-9504
Ruben MesaCenter on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, TX, United States.ORCID https://orcid.org/0000-0001-5880-7972
Gail E TomlinsonCenter on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, TX, United States.ORCID https://orcid.org/0000-0003-2579-1833
Jing WangCenter on Smart and Connected Health Technologies, Mays Cancer Center, School of Nursing, UT Health San Antonio, San Antonio, TX, United States.ORCID https://orcid.org/0000-0002-4012-0977

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
NCI NIH HHS P30 CA054174
6 · The paper itself

Abstract

Cancer is a leading cause of death in the United States and across the globe. Cancer screening is an effective preventive measure that can reduce cancer incidence and mortality. While cancer screening is integral to cancer control and prevention, due to the COVID-19 outbreak many screenings have either been canceled or postponed, leaving a vast number of patients without access to recommended health care services. This disruption to cancer screening services may have a significant impact on patients, health care practitioners, and health systems. In this paper, we aim to offer a comprehensive view of the impact of COVID-19 on cancer screening. We present the challenges COVID-19 has exerted on patients, health care practitioners, and health systems as well as potential opportunities that could help address these challenges.

Indexed as

brandingcampaigncancercobrandingcoronavirusCOVID-19educationhealthscreeningsocial determinantssocial mediatelemedicinetraining

Identifiers

PMID33027039
PMCPMC7599065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.